CD27
CD27 antigen
As of the edition of 20 October 2026, CD27 (CD27 antigen, UniProt P26842) has 3 drugs tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P26842
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Blood and lymph; Immune system; Urinary and reproductive; Digestive system; Hormones
- Registered trials of its drugs
- 16
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Varlilumab | Stopped | Phase 2 | none listed |
| Boserolimab | Active | Phase 2 | none listed |
| CDX-527 | Status not established | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 2 |